Literature DB >> 11182035

Expression of E-cadherin and beta-catenin in primary and peritoneal metastatic ovarian carcinoma.

T Fujioka1, Y Takebayashi, T Kihana, Y Kusanagi, K Hamada, H Ochi, T Uchida, M Fukumoto, M Ito.   

Abstract

Protein expression levels of E-cadherin and beta-catenin were examined in 39 primary and 10 metastatic ovarian carcinoma to elucidate the role of these molecules in the extension of ovarian carcinoma by immunohistochemistry. Twenty-two of 39 (56%) ovarian carcinomas were preserved type and 17 of 39 (44%) were reduced type of E-cadherin. In contrast, 36 of 39 (92%) ovarian carcinomas were preserved type and 3 of 39 (8%) were reduced type of beta-catenin. E-cadherin expression in well-differentiated carcinoma was higher than that in moderately/poorly-differentiated carcinoma (p<0.05). Interestingly, 6 of 10 (60%) peritoneal metastatic lesions resulted in the reduced expression of E-cadherin compared with primary lesions. In contrast, only 2 of 10 (20%) metastatic lesions showed reduced expression of beta-catenin compared with primary lesions. Mutation of exon 3 of beta-catenin gene was rare (3%, 1/39) in carcinoma. These results suggested that the cell adhesion molecule E-cadherin might play an important role in the formation of peritoneal metastasis. In contrast, beta-catenin is not a good indicator of metastasis in human ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11182035

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  12 in total

1.  Integrin regulation of beta-catenin signaling in ovarian carcinoma.

Authors:  Rebecca J Burkhalter; Jaime Symowicz; Laurie G Hudson; Cara J Gottardi; M Sharon Stack
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

2.  Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer.

Authors:  Yu Yuecheng; Li Hongmei; Xin Xiaoyan
Journal:  Clin Exp Metastasis       Date:  2006-07-07       Impact factor: 5.150

3.  Biomarker expression in normal fimbriae: Comparison of high- and low-grade serous ovarian carcinoma.

Authors:  Zhang Xuyin; Ding Jingxin; Tao Xiang; Jia Luoqi; Hua Keqin
Journal:  Oncol Lett       Date:  2012-08-23       Impact factor: 2.967

4.  Establishment and characterization of a human uterine endometrial undifferentiated carcinoma cell line, TMG-L.

Authors:  Kiyoshi Hasegawa; Machiko Suzuki; Kunimi Ishikawa; Akira Yasue; Rina Kato; Azumi Nakamura; Jun Kuroki; Yasuhiro Udagawa
Journal:  Hum Cell       Date:  2003-03       Impact factor: 4.174

5.  Relationship between expression of E-cadherin-catenin complex and clinicopathologic characteristics of pancreatic cancer.

Authors:  Yu-Jun Li; Xiang-Rui Ji
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

6.  Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer.

Authors:  K A Voutilainen; M A Anttila; S M Sillanpää; K M Ropponen; S V Saarikoski; M T Juhola; V-M Kosma
Journal:  J Clin Pathol       Date:  2006-02-03       Impact factor: 3.411

Review 7.  Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression.

Authors:  Laurie G Hudson; Reema Zeineldin; M Sharon Stack
Journal:  Clin Exp Metastasis       Date:  2008-04-09       Impact factor: 5.150

8.  The traditional Tibetan medicine Yukyung Karne exhibits a potent anti-metastatic activity by inhibiting the epithelial to mesenchymal transition and cell migration.

Authors:  Tenzin Choedon; Ganeshan Mathan; Vijay Kumar
Journal:  BMC Complement Altern Med       Date:  2015-06-13       Impact factor: 3.659

Review 9.  Targeting TBP-Associated Factors in Ovarian Cancer.

Authors:  Jennifer R Ribeiro; Lindsay A Lovasco; Barbara C Vanderhyden; Richard N Freiman
Journal:  Front Oncol       Date:  2014-03-11       Impact factor: 6.244

10.  Plakoglobin Reduces the in vitro Growth, Migration and Invasion of Ovarian Cancer Cells Expressing N-Cadherin and Mutant p53.

Authors:  Mahsa Alaee; Ghazal Danesh; Manijeh Pasdar
Journal:  PLoS One       Date:  2016-05-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.